Laser-Based mRNA Characterization Could Reshape Biologics Release Testing

University at Albany researchers are developing a laser-based analytical method aimed at characterizing mRNA vaccines and therapies without destroying the sample, a capability that could have direct implications for release testing workflows and sample conservation in GMP manufacturing environments. For QA teams managing biologics production, where every dose carries significant cost and limited batch volumes constrain destructive testing, a validated non-destructive technique would represent a meaningful shift in how in-process and final release analytics are structured.

The research focuses on using laser technology to evaluate some of the most structurally sensitive drug products currently in development, including mRNA vaccines and related therapies. The stated objective is to provide pharmaceutical manufacturers with a faster, more practical tool for product characterization, one that preserves the tested dose rather than consuming it. For facilities operating under 21 CFR Part 211 and ICH Q10 quality systems, integrating such a method into existing analytical workflows would require rigorous method validation, but the potential to reduce sample waste while maintaining or improving assay sensitivity is a proposition worth tracking.

Non-destructive testing is not new to pharmaceutical quality control, but its application to mRNA and biologics QC remains limited. Current release testing for mRNA products typically involves techniques that consume sample material, creating tension between thorough characterization and dose availability, particularly during early-phase manufacturing or when working with high-value, low-volume batches. A laser-based approach that can deliver reliable characterization data without sample loss could ease that constraint, provided it meets the specificity, precision, and robustness standards required under GMP.

The work remains at the academic stage, and no timeline has been disclosed for industry adoption or regulatory submission of the method. Plant heads and analytical development leads should note, however, that academic innovations of this type frequently signal the direction of future compendial and regulatory expectations. As the biologics pipeline continues to expand, particularly in mRNA-based modalities, demand for analytical tools that balance throughput, sensitivity, and sample preservation will only intensify.

Source: Pharmaceutical Industry News, published April 16, 2026. Original reporting via EIN News.